Le Lézard
Classified in: Health
Subject: STP

My Patient Rights Reminds Californians of New Law Requiring Co-Prescribing of Overdose Reversal Drugs to Combat Opioid Crisis


SACRAMENTO, Calif., Jan. 16, 2019 /PRNewswire/ -- My Patient Rights and the California Chronic Care Coalition are reminding Californians to make sure that they and their family members are aware of a new law that takes another step in addressing the opioid crisis. This law states that prescribers of pain-relieving opioids must also offer a prescription for the opioid-overdose reversal drug, naloxone, to high-risk patients. AB 2760 was passed overwhelmingly by the California Legislature and signed into law in September 2018 by Gov. Edmund G. Brown, Jr.

California Chronic Care Coalition/My Patient Rights (PRNewsfoto/California Chronic Care Coaliti)

Accidental opioid overdoses account for about 80 percent of all opioid emergencies and 83 percent of prescription opioid-related deaths are unintended or accidental. While anyone taking opioids is at potential risk for an overdose, there are certain high-level, at-risk groups that are susceptible, so being prepared with the overdose reversal drug, naloxone, in close proximity is essential.

This problem has become so acute that the U.S. Surgeon General issued its first advisory in 13 years recommending emergency treatments like naloxone ? which is so important to saving lives ? be available for consumer use.

"For patients with chronic illness, pain relieving opioids are a lifeline but the risk of an overdose increases the more you take to combat the pain," said Liz Helms, president and CEO of the California Chronic Care Coalition. "Requiring naloxone to be offered at the same time as prescribing an opioid pain medication will go a long way in preventing accidental overdoses and needless deaths. And since many caregivers are family members, it is important to make them aware that this potentially life-saving emergency treatment will be more readily available when opioids are prescribed."

There are many reasons for accidental opioid overdose emergencies and these emergencies can occur even when opioids are used as directed. Those at high risk for accidental opioid overdose include:

In 2016, more than 214 million prescriptions were written and filled for opioids. With this many patients taking opioids for medical conditions and medical procedures, it's important to have the discussion and prepare for potential overdoses.

"Naloxone is a tool that can immediately save lives. And I hope this new law will provide an opportunity for discussion of the potential for accidental opioid overdose and how to prevent it," said Assemblymember Jim Wood (D-Santa Rosa), author of AB 2760.

Anyone who uses opioids for pain control is at risk for an opioid overdose emergency. Now that naloxone co-prescription for high risk individuals is the law in California, make sure you and your families are prepared for the unexpected by talking about opioids, the potential for overdose even when used correctly, having naloxone with you, and recognizing the signs of overdose:

Knowing the risks, recognizing the signs and having naloxone on-hand will go a long way in potentially saving a life from accidental opioid overdose.

About My Patient Rights and the California Chronic Care Coalition                               

My Patient Rights was launched by the California Chronic Care Coalition to help people who have been denied treatment or medicines, experienced delays or are dissatisfied with the decisions made by their health plan.

The California Chronic Care Coalition (CCCC) is a unique alliance of more than thirty leading consumer health organizations and provider groups that engage policy makers, industry leaders, providers and consumers to improve the health of Californians with chronic conditions. We envision a system of care that is accessible, affordable and of a high quality that emphasizes prevention, coordinated care and the patient's wellness and longevity.

 

SOURCE My Patient Rights; California Chronic Care Coalition


These press releases may also interest you

at 17:25
Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted...

at 16:56
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...

at 16:28
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument? ?QOL-B...

at 16:20
Jarrard Inc., a leading national healthcare strategic communications consultancy, has expanded by 10 percent, adding seven new professionals to address the increasing demand for its healthcare advisory services. The team now includes 81 full-time...

at 16:10
Pulse Biosciences, Inc. ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, today announced that the Company's Board of Directors has determined a new record...

at 16:10
Contineum Therapeutics, Inc. , a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of...



News published on and distributed by: